Ask AI
ProCE Banner Activity

New Targeted Therapies and Emerging Data in Urothelial Carcinoma

Slideset
Review expert guidance on integrating erdafitinib and enfortumab vedotin into management of progressive urothelial carcinoma, then get up to date on key data for sacituzumab govitecan and other promising investigational therapies.

Released: February 26, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Immunomedics

Faculty Disclosure

Primary Author

Petros Grivas, MD, PhD, FASCO

Professor, Dept. of Medicine, Division of Hematology Oncology
University of Washington
Professor, Clinical Research Division
Medical Director, International Program and Local/Regional Outreach
Fred Hutch Cancer Center
Seattle, Washington